Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05973214
Recruiting Not applicable

Effectiveness of a Cognitive and Behavioral Treatment Program in People With Idiopathic Environmental Intolerance (IEI)

NCT05973214 · tracked via the Priya Life Science France tracker
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Not applicable
Started
2024-02-20
Last updated
2025-08-13

Condition(s) studied

Idiopathic Environmental Intolerance

Investigational drug(s) / intervention(s)

Cognitive Behavioral Therapy

Cognitive Behavioral Therapy: CBT for IEI

Study summary

Idiopathic Environmental Intolerance (IEI) denotes a functional disorder represented by heterogeneous symptoms that sufferers attribute to specific environmental agents and for which there may be no solid evidence of an underlying physiological cause.

We are conducting a randomized controlled trial study to compare patients before and after a newly developed cognitive behavioral therapy treatment program for IEI, with respect to behavioral and psychometric variables.

The results of this research project are expected to contribute to advancements in the clinical treatment of IEI, as well as to elaborate on existing theoretical models of IEI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥18 years, * Present a diagnosis of idiopathic environmental intolerance confirmed by the lead physician at the admission * Be affiliated to a social security regime. * Informed Consent Exclusion Criteria: * Severe depression, delusion disorder or substance use disorder * No access to internet * Non-French speakers * Currently participating to another research on IEI * Under an exclusion period for another study * Benefiting from French state aid known as AME * Deprivation of liberty by court or administrative order * Hospitalized without consent * Under protective measures * Pregnancy and/or breastfeeding

Primary outcome measure(s)

  • Short Form Health Survey - 12 — T0; 3 Months ; 6 Months
    Measures quality of life with a minimum value of zero and a maximum value of 100. Higher score indicates better outcome.

Trial sites (1)

FacilityCityRegionStatus
Unité de pathologies professionnelles et environnementales, Hôtel-Dieu Paris Paris Recruiting

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

French Childhood Cancer Survivor Study Recruiting
Neural Correlates of Movement Disorders Associated With PRRT2 Related Paroxysmal Kinesigenic Dyskinesia - an Ancillary Study of AMEDYST Research Recruiting
Validation and Implementation of 3T MRI Research Protocols Recruiting
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms Recruiting
Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05973214 on ClinicalTrials.gov ↗ ← All trials in France